Ignite Creation Date:
2024-05-06 @ 5:45 PM
Last Modification Date:
2024-10-26 @ 2:34 PM
Study NCT ID:
NCT05410470
Status:
COMPLETED
Last Update Posted:
2022-06-08
First Post:
2022-05-23
Brief Title:
Efficacy and Safety of Ruxolitinib in Patients With Myelofibrosis
Sponsor:
Qilu Hospital of Shandong University
Organization:
Qilu Hospital of Shandong University
Study Overview
Official Title:
Efficacy and Safety of Ruxolitinib in Patients With Myelofibrosis A Retrospective Multicenter Study
Status:
COMPLETED
Status Verified Date:
2022-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Ruxolitinib is a Janus kinase JAK 12 inhibitor currently used in the treatment of Myelofibrosis MF Ruxolitinib confirmed improvements in splenomegaly MF-related symptoms and survival benefit in COMFORT and JUMP studies At present the real-world data on the efficacy and safety of ruxolitinib in the treatment of MF in China is still insufficient The aim of this study was to evaluate the efficacy and safety of ruxolitinib in patients with MF and to provide guidance for the usage of ruxolitinib in MF in ChinaThis was a retrospective multicenter study of MF patients who received ruxolitinib treatment in Shandong province from August 2012 to December 2021 Data were analyzed using SPSS Overall survival OS and Event-free survival EFS were estimated using the Kaplan- Meier method
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None